Latest Period
Q4 2025
Security Snapshot
Lyell Immunopharma, Inc. - Common Stock (LYEL) Institutional Ownership
CUSIP: 55083R104
13F Institutional Holders and Ownership History from Q2 2021 to Q4 2025
Institutions Reporting
1
Shares (Excl. Options)
692,050
Price
$30.78
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock
- Symbol
- LYEL on Nasdaq
- Shares outstanding
- 21,259,732
- Price per share
- $30.78
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 692,050
- Total reported value
- $21,301,299
- % of total 13F portfolios
- 0%
- Share change
- +96,584
- Value change
- +$2,972,856
- Number of holders
- 1
- Price from insider filings
- $30.78
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- LYEL - Lyell Immunopharma, Inc. - Common Stock is tracked under CUSIP 55083R104.
- 1 institution reported positions in Q4 2025.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 2 to 1 between Q3 2025 and Q4 2025.
- Reported value moved from $10,561,733 to $21,301,299.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 1 institution filings for Q4 2025.
Investment Quick Answers
What is CUSIP 55083R104?
CUSIP 55083R104 identifies LYEL - Lyell Immunopharma, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 55083R104:
Significant Owners of Lyell Immunopharma, Inc. - Common Stock (LYEL) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. | 13% | $17,200,927 | 36,597,716 | Robert Nelsen | 31 Dec 2024 | |||
| Foresite Capital Fund IV, L.P. | 9.2% | +36% | $12,766,089 | +$3,611,010 | 27,161,892 | +39% | James B. Tananbaum | 31 Mar 2025 |
| BlackRock, Inc. | 4.5% | $6,234,958 | 13,265,869 | BlackRock, Inc. | 31 Dec 2024 | |||
| Euler Fund, L.P. | 6.7% | $43,908,532 | 1,426,528 | EULER FUND, L.P. | 06 Mar 2026 | |||
| Explore Investments LLC/DE | 5.4% | $9,202,122 | 1,040,964 | Explore Investments LLC | 25 Jul 2025 |
As of 31 Dec 2025, 1 institutional investors reported holding 692,050 shares of Lyell Immunopharma, Inc. - Common Stock (LYEL). This represents 3.3% of the company’s total 21,259,732 outstanding shares.
Institutional Holders of Lyell Immunopharma, Inc. - Common Stock (LYEL) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 692,050 | $21,301,299 | +$2,972,856 | $30.78 | 1 |
| 2025 Q3 | 650,353 | $10,561,733 | -$15,728,473 | $16.24 | 2 |
| 2025 Q2 | 2,440,673 | $21,579,143 | -$465,374,774 | $8.84 | 6 |
| 2025 Q1 | 152,354,676 | $81,758,597 | +$815,972 | $0.54 | 111 |
| 2024 Q4 | 150,286,895 | $95,884,372 | +$14,590,328 | $0.64 | 101 |
| 2024 Q3 | 128,413,620 | $176,562,559 | -$7,293,208 | $1.38 | 115 |
| 2024 Q2 | 133,365,913 | $193,952,761 | -$1,433,462 | $1.45 | 114 |
| 2024 Q1 | 132,843,101 | $296,874,901 | +$3,769,415 | $2.23 | 124 |
| 2023 Q4 | 131,309,565 | $255,237,592 | +$1,520,026 | $1.94 | 116 |
| 2023 Q3 | 122,510,290 | $180,096,177 | +$237,767 | $1.47 | 102 |
| 2023 Q2 | 122,233,983 | $388,698,764 | +$15,244,327 | $3.18 | 98 |
| 2023 Q1 | 117,770,423 | $277,898,040 | +$604,828 | $2.36 | 97 |
| 2022 Q4 | 116,732,928 | $404,998,862 | +$13,810,466 | $3.47 | 94 |
| 2022 Q3 | 112,406,834 | $823,966,061 | +$50,675,691 | $7.33 | 88 |
| 2022 Q2 | 105,615,240 | $688,647,561 | +$42,215,226 | $6.52 | 72 |
| 2022 Q1 | 99,521,989 | $502,714,970 | +$55,442,935 | $5.05 | 78 |
| 2021 Q4 | 85,540,866 | $662,180,000 | -$22,122,993 | $7.74 | 76 |
| 2021 Q3 | 82,534,412 | $1,221,509,324 | +$39,832,274 | $14.80 | 61 |
| 2021 Q2 | 79,701,853 | $1,294,200,800 | +$1,294,200,800 | $16.24 | 52 |